Merck KGaA, Personalis team up on cancer biomarkers

By staff writers

November 19, 2019 -- Merck KGaA will use the ImmunoID NeXT immunogenomics platform of Personalis to develop biomarkers for cancer therapies through a new collaboration.

Personalis' platform is designed to provide information about cancer genomics and the tumor microenvironment for use in developing novel biomarkers. It takes into account mutation status, immune repertoire, resistance mechanisms, DNA repair pathways, tumor mutational burden (TMB), and microinstability status, among other factors involved in response to cancer therapies, Personalis said.

Merck KGaA markets the programmed cell death ligand 1 (PD-L1) checkpoint inhibitor avelumab jointly with Pfizer and has other cancer immunotherapies in development.

HalioDx, Kite expand work on immuno-oncology biomarkers
Immuno-oncology company HalioDx and Gilead subsidiary Kite are expanding their biomarker development partnership to move beyond diffuse large B-cell lymphoma...
PathAI reports algorithm on par in PD-L1 immunotherapy studies
PathAI reported that its pathology artificial intelligence algorithm performed on par or better than board-certified pathologists in retrospective immunotherapy...
Promega, Merck team up on Keytruda companion test
Promega and Merck announced a collaboration to develop a polymerase chain reaction companion diagnostic to evaluate microsatellite instability for use...
Personal Genome Diagnostics touts liquid biopsy data
Personal Genome Diagnostics reported positive study results for a 58-gene panel liquid biopsy test for assessing microsatellite instability and tumor...
Liquid biopsy test detects biomarker for immunotherapy
Precision oncology company Guardant Health is touting a new study confirming that its Guardant360 liquid biopsy test can accurately detect microsatellite...

Copyright © 2019

Last Updated np 11/19/2019 1:00:49 PM